NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX)
Post# of 231
(Total Views: 290)
Posted On: 12/08/2020 3:46:55 PM
NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Finalizes Technology Transfer of Manufacturing Process for Novel Gene Therapy
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has reached a significant milestone. The company successfully completed the technology transfer of its manufacturing process for the production of its lead candidate for immunogene therapy, REQORSA(TM). The transfer was made from the major cancer research institution where it had previously been manufactured to experienced, commercial contract development and manufacturing organizations (“CDMOs”). This step marks the first time REQORSA has been manufactured outside of the research institution where it was discovered and at commercial scale in a current Good Manufacturing Practices (“cGMP”)-compliant facility. According to the company, the move will provide production and process improvements that will result in a reliable, scalable, reproducible and stable drug product suitable for storage, shipment and patient use. “The successful completion of our manufacturing technology transfer represents a major milestone for Genprex,” said Genprex president and CEO Rodney Varner in the press release. “We are delighted to collaborate with leading, global CDMOs that have enabled us to complete the successful engineering batch. We are now focused on the completion of commercial scale production of REQORSA, for use in our two upcoming clinical trials. At the same time, our clinical group is engaging with clinical trial sites who will recruit and treat patients related to our clinical trials.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has reached a significant milestone. The company successfully completed the technology transfer of its manufacturing process for the production of its lead candidate for immunogene therapy, REQORSA(TM). The transfer was made from the major cancer research institution where it had previously been manufactured to experienced, commercial contract development and manufacturing organizations (“CDMOs”). This step marks the first time REQORSA has been manufactured outside of the research institution where it was discovered and at commercial scale in a current Good Manufacturing Practices (“cGMP”)-compliant facility. According to the company, the move will provide production and process improvements that will result in a reliable, scalable, reproducible and stable drug product suitable for storage, shipment and patient use. “The successful completion of our manufacturing technology transfer represents a major milestone for Genprex,” said Genprex president and CEO Rodney Varner in the press release. “We are delighted to collaborate with leading, global CDMOs that have enabled us to complete the successful engineering batch. We are now focused on the completion of commercial scale production of REQORSA, for use in our two upcoming clinical trials. At the same time, our clinical group is engaging with clinical trial sites who will recruit and treat patients related to our clinical trials.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)